MedTrace Logo

Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

NCT03693547 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-01-10

No results posted yet for this study

Summary

To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic NSCLC as a phase II trial

Conditions

Interventions

DRUG

utidelone injection

utidelone monotherapy in patients with advanced NSCLC by utidelone

Sponsors & Collaborators

  • Chengdu Biostar Pharmaceuticals

    collaborator INDUSTRY

  • Beijing Biostar Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • YUANKAI SHI, MD, PhD · National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-22
Primary Completion
2021-06-25
Completion
2021-08-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03693547 on ClinicalTrials.gov